Humacyte, Inc. (NASDAQ:HUMA) Given Average Rating of “Moderate Buy” by Analysts

Humacyte, Inc. (NASDAQ:HUMA) has received a consensus rating of “Moderate Buy” from the eight brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $6.25.

Several brokerages recently commented on HUMA. TD Cowen decreased their target price on shares of Humacyte from $1.50 to $1.25 and set a “buy” rating on the stock in a research note on Wednesday, June 17th. Wall Street Zen raised shares of Humacyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. D. Boral Capital reissued a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research report on Tuesday, April 28th. BTIG Research reissued a “buy” rating and set a $2.00 price objective on shares of Humacyte in a research report on Tuesday, June 16th. Finally, HC Wainwright boosted their price objective on shares of Humacyte from $3.00 to $4.00 and gave the company a “buy” rating in a research report on Thursday, June 11th.

Insider Buying and Selling at Humacyte

In other Humacyte news, insider Shamik J. Parikh sold 45,887 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $0.90, for a total transaction of $41,298.30. Following the transaction, the insider directly owned 272,713 shares of the company’s stock, valued at approximately $245,441.70. The trade was a 14.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Dale A. Sander sold 45,887 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $0.90, for a total transaction of $41,298.30. Following the transaction, the chief financial officer directly owned 267,213 shares in the company, valued at approximately $240,491.70. The trade was a 14.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Sei Investments Co. purchased a new position in Humacyte during the 1st quarter valued at $56,000. R Squared Ltd increased its position in Humacyte by 140.5% during the 1st quarter. R Squared Ltd now owns 62,911 shares of the company’s stock valued at $38,000 after purchasing an additional 36,758 shares during the period. Private Advisor Group LLC increased its position in Humacyte by 48.3% during the 1st quarter. Private Advisor Group LLC now owns 832,799 shares of the company’s stock valued at $505,000 after purchasing an additional 271,222 shares during the period. Wealth Effects LLC increased its position in Humacyte by 33.6% during the 1st quarter. Wealth Effects LLC now owns 204,500 shares of the company’s stock valued at $124,000 after purchasing an additional 51,433 shares during the period. Finally, Caitong International Asset Management Co. Ltd increased its position in Humacyte by 841.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 70,414 shares of the company’s stock valued at $68,000 after purchasing an additional 62,931 shares during the period. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte Price Performance

Shares of NASDAQ HUMA opened at $0.92 on Monday. The company has a quick ratio of 3.32, a current ratio of 3.93 and a debt-to-equity ratio of 5.46. Humacyte has a 52 week low of $0.55 and a 52 week high of $2.84. The firm’s fifty day moving average is $0.99 and its 200 day moving average is $1.02. The company has a market cap of $205.24 million, a price-to-earnings ratio of -1.62 and a beta of 2.45.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Wednesday, May 13th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. Humacyte had a negative net margin of 4,836.06% and a negative return on equity of 2,914.18%. The company had revenue of $0.50 million for the quarter, compared to the consensus estimate of $1.46 million. On average, equities research analysts expect that Humacyte will post -0.34 earnings per share for the current year.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.